Recurrent Epstein-Barr Virus-positive (EBV+) Primary Central Nervous System Lymphoma (PCNSL) in a Patient with Clinical Features of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS)

Intern Med. 2019;58(6):849-854. doi: 10.2169/internalmedicine.1246-18. Epub 2019 Mar 15.

Abstract

Primary central nervous system lymphoma (PCNSL) and chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS) can share clinical features and may be indistinguishable, even after brain biopsy. We encountered a case of Epstein-Barr virus-positive (EBV+) PCNSL recurrence in a patient with clinical features of CLIPPERS, and repeat brain biopsy was required to reach the correct diagnosis. Four years after the initial diagnosis and treatment of PCNSL, "peppering" punctate enhanced lesions with transient steroid responsiveness were detected during brain magnetic resonance imaging (MRI). A second brain biopsy supported a diagnosis of CLIPPERS, while a third biopsy confirmed the diagnosis of recurrent PCNSL.

Keywords: Epstein-Barr virus (EBV); chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS); primary central nervous system lymphoma (PCNSL); recurrence; repeat brain biopsy.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Brain Stem Neoplasms / drug therapy*
  • Brain Stem Neoplasms / genetics*
  • Brain Stem Neoplasms / pathology
  • Central Nervous System Neoplasms / genetics*
  • Central Nervous System Neoplasms / pathology
  • Chronic Disease
  • Herpesvirus 4, Human / genetics*
  • Herpesvirus 4, Human / pathogenicity
  • Humans
  • Inflammation / genetics*
  • Inflammation / pathology
  • Lymphocytes / drug effects
  • Lymphocytes / pathology
  • Lymphoma / genetics*
  • Lymphoma / pathology
  • Male
  • Methylprednisolone / therapeutic use*
  • Neoplasm Recurrence, Local / genetics
  • Neoplasm Recurrence, Local / pathology
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Methylprednisolone